Take This Peptide, Heal Faster? | Lifespan with Dr. David Sinclair - S2, Ep. 12 | David Sinclair

The Gist

Peptides like BPC 157 and MOTS-c show intriguing mechanistic promise for health and longevity, but human clinical trial evidence remains largely thin or absent, meaning they function primarily as unproven research compounds. Most peptides sold online operate as gray market or research only products with no FDA approval for aging.

Quick Overview

Dr. David Sinclair and Matt explore the science, claims, and regulatory landscape of longevity peptides, mitochondrially derived peptides, and cellular senescence treatments. The discussion breaks down specific compounds including MOTS-c, SS-31, FOXO4-DRI, Humanin, BPC 157, and PT-141, separating validated medical indications from widespread off-label and gray market usage. While certain animal studies demonstrate dramatic healing and rejuvenation effects, human clinical data is severely limited outside of specific orphan indications.

Key Points: MOTS-c is a 16 amino acid mitochondrial derived peptide encoded in mitochondrial DNA that improves metabolism and acts as an exercise mimetic in mice. SS 31, also known as Elamipretide and developed by Dazheh and Schiller, achieved FDA approval in 2025 for treating Barth syndrome as the first FDA approved drug to target mitochondria. FOXO4-DRI is an engineered peptide that disrupts the interaction between FOXO4 and p53 to induce apoptosis in senescent zombie cells, reversing aging signs in TTD mutant mice. BPC 157 is a synthetic peptide derived from a human gastric juice protein that shows rapid tendon and ligament healing in rat studies but lacks rigorous human clinical trials. Bremelanotide or PT 141 is an FDA approved peptide sold under the brand name Vyleesi that targets the brain hypothalamus to treat hypoactive sexual desire disorder in women. Humanin is a 24 amino acid mitochondrial derived peptide discovered in Japan in 2001 that protects neurons and reduces inflammation by downregulating the NLRP3 inflammasome. GLP 2 analog Teduglutide achieved FDA approval for short bowel syndrome based on a 24 week clinical trial demonstrating a 63 percent response rate in liquid nutrition reduction.